Audiences and critics tend to gravitate towards actors that they like, even if their acting isn't really all that impressive.

D4vd, whose real name is David Burke, is accused of killing Celeste Rivas, 14, whose mutilated remains were found in his ...

Rockstar has been teasing the sound of GTA VI since the game's first trailer arrived in 2023. That trailer was soundtracked ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company looks to be in late ...

Braveheart Bio (Nasdaq: BRVE), a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, ...

Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions. The San Francisco-based biotech had previously sketched out a ...

SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy ...

Braveheart Bio, Inc. (BRVE) has filed proposed terms for a $300 million IPO of its common stock, per an SEC S-1/A registration statement. The firm is a clinical-stage biopharma developing a treatment ...

Braveheart Bio has launched a US$318.8m Nasdaq IPO that will provide funds for US trials on a heart disease drug it licensed from China’s Jiangsu Hengrui Pharmaceuticals last year. The offering was ...

Braveheart Bio’s Nasdaq IPO (BRVE) targets $15–$17/share for 18.75M shares, featuring Fidelity’s $75M indicated interest and multi-bank syndicate led by Goldman Sachs and Jefferies. BHB-1893, sourced ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The three largest life sciences ...

Clinical-stage biopharma companies Braveheart Bio (BRVE) and Attovia Therapeutics (ATTO) have announced plans to raise $274.5M and $182.4M in net proceeds, respectively, from their initial public ...